Tsubata, Yukari
Hotta, Takamasa
Hamai, Kosuke
Furuya, Naoki
Yokoyama, Toshihide
Saito, Ryota
Nakamura, Atsushi
Masuda, Takeshi
Hamaguchi, Megumi
Kuyama, Shoichi
Honda, Ryoichi
Senoo, Tadashi
Nakanishi, Masamoto
Yamasaki, Masahiro
Ishikawa, Nobuhisa
Fujitaka, Kazunori
Kubota, Tetsuya
Kobayashi, Kunihiko
Isobe, Takeshi
Funding for this research was provided by:
Daiichi Sankyo Company (LIX-MD-15003)
Article History
Received: 21 January 2022
Accepted: 26 March 2022
First Online: 4 April 2022
Declarations
:
: This study was conducted in accordance with the principles of the Declaration of Helsinki and the Good Clinical Practice Guidelines. The study protocol was approved by the Shimane University Institutional Review Board based on the Clinical Trials Act enacted in Japan in 2017 and published in the Japan Registry of Clinical Trials (jRCTs061180025). Written informed consent was obtained from all patients.
: Not applicable.
: Outside of the submitted work, YT received personal fees and a grant from Daiichi Sankyo Co., Ltd. and AstraZeneca K.K. and personal fees from Chugai Pharmaceuticals Inc.; NF received personal fees from AstraZeneca K.K., Chugai Pharmaceutical, Nippon Boehringer Ingelheim Co., Ltd., Bristol-Myers Squibb Company, Eli Lilly Japan K.K., MSD K.K., Pfizer Japan Inc. Taiho Pharmaceutical, and Novartis Pharma K.K.; TY received personal fees from Eli Lilly Japan K.K., Merck Sharp & Dohme K.K., and Takeda Pharmaceutical; AN received personal fees and a grant from AstraZeneca K.K., Thermo Fisher Scientific, Inc., Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Novartis Pharma K.K., Pfizer Japan Inc., and Nippon Kayaku Co., Ltd. and personal fees from Taiho Pharmaceutical Co., Ltd.; TM received personal fees from AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Eli Lilly Japan, Nippon Boehringer Ingelheim Co., Ltd., Kyowa Kirin Co., Ltd., and Ono Pharmaceutical Co., Ltd.; KF received personal fees from AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., Bristol-Myers Squibb Company, MSD K.K., Pfizer Japan Inc., Daiichi Sankyo Co., Ltd., Eli Lilly Japan, and Nippon Boehringer Ingelheim Co., Ltd.; KK received personal fees from AstraZeneca K.K. and Takeda Pharmaceutical; and TI received personal fees and a grant from Daiichi Sankyo Co., Ltd., personal fees from AstraZeneca K.K., Pfizer Japan Inc., and Nippon Boehringer Ingelheim Co., Ltd., and grants from Pearl Therapeutics Inc. and Janssen Pharmaceutical K.K.